Beauvericin and enniatins H, I and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase
- Authors
- Shin, Cha-Gyun; An, Dog-Gn; Song, Hyuk-Hwan; Lee, Chan
- Issue Date
- Dec-2009
- Publisher
- JAPAN ANTIBIOTICS RESEARCH ASSOC
- Keywords
- beauvericin; enniatins; HIV-1; inhibitor; integrase
- Citation
- JOURNAL OF ANTIBIOTICS, v.62, no.12, pp 687 - 690
- Pages
- 4
- Journal Title
- JOURNAL OF ANTIBIOTICS
- Volume
- 62
- Number
- 12
- Start Page
- 687
- End Page
- 690
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/22878
- DOI
- 10.1038/ja.2009.102
- ISSN
- 0021-8820
1881-1469
- Abstract
- Some enniatins (ENs) reportedly exhibit antiretroviral activities in vivo. The potential inhibitory activities of cyclic hexadepsipeptides such as beauvericin (BEA) and ENs H, I and MK1688 were investigated in vitro against human immunodeficiency virus type-1 (HIV-1) integrase and Moloney murine leukemia virus reverse transcriptase. BEA, EN I and EN MK1688 exhibited strong inhibitory activities against HIV-1 integrase, whereas EN H showed relatively weak activity. None of the examined compounds showed anti-reverse transcriptase activity. BEA was the most effective inhibitor of the tested cyclic hexadepsipepticles in inhibiting HIV-1 integrase. These results indicate the potential of cyclic hexadepsipeptides as a new class of potent inhibitors of HIV-1 integrase. The Journal of Antibiotics (2009) 62, 687-690; doi:10.1038/ja.2009.102; published online 6 November 2009
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Biotechnology & Natural Resource > Department of Systems Biotechnology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.